Intelligence / Healthtech / New Clinical Trials / Jiangsu Simcere Pharmaceutical Co., Ltd.
Jiangsu Simcere Pharmaceutical Co., Ltd.
29 Oct 2026: Trial registered · A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 29 Oct 2026
- Title
- A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke
- Conditions
- Acute Ischemic Stroke AIS
- Phase
- Phase 2, Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07903701
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Jiangsu Simcere Pharmaceutical Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Jiangsu Simcere Pharmaceutical Co., Ltd. in our registers.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.